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RI-Targeted Fusion Proteins Result in Efficient Presentation by Human 
Monocytes of Antigenic and Antagonist T Cell Epitopes
 

























A major challenge for using native or modified T cell
epitopes to induce or suppress immunity relates to poor lo-
calization of peptides to antigen presenting cells (APCs) in
vivo. In this study, we demonstrate enhanced presentation
of antigenic and antagonistic peptides by targeting them to
 




RI, CD64) on human
monocytes. A Th epitope of tetanus toxoid, TT830, and the
antagonistic peptide for TT830, TT833S, were genetically
grafted into the constant region of the heavy chain of the
humanized anti-CD64 mAb 22 and expressed as monova-
lent fusion proteins, Fab22-TT830 and Fab22-TT833S.
These CD64-targeted peptides were up to 1,000- and 100-
fold more efficient than the parent peptides for T cell stimu-
lation and antagonism, respectively, suggesting that such
fusion proteins could effectively increase the delivery of





tagonistic peptide inhibited proliferation of TT830-specific
T cells even when APCs were first pulsed with native pep-
tide, a situation comparable with that which would be en-
countered in vivo when attempting to ameliorate an au-
toimmune response. These data suggest that targeted
presentation of antagonistic peptides could lead to promis-





























Increased understanding of antigen recognition by the im-
mune system has provided a theoretical basis for designing im-
munogenic peptide-based vaccines (1–3). Peptide vaccines can
be more effective than traditional vaccines consisting of either
killed or attenuated pathogenic organisms for a variety of rea-
sons. By selection from within a given protein Ag of only the
epitopes which confer protective immunity, peptide-based vac-
cines can exclude determinants that could elicit a deleterious
immune response and avoid the potentially infectious materi-
als contained in traditional vaccines. Use of peptide-based vac-
cines to boost immune responses against cryptic tumor anti-
genic determinants has special significance in the development
of immunotherapy for cancer treatment (4, 5), where one goal
is to break the immune tolerance of dominant tumor antigens.
However, the development of peptide vaccines has been
impeded by the usually poor immunogenicity of peptides due,





 in vivo. One way to overcome this prob-
lem has been through the development of the so-called anti-
genized Ab (AgAb) in which antigenic determinants are
grafted into the variable region of IgG (6, 7). This method is
effective because it increases the half-life of the Ag and facili-




R. However, some drawbacks
still remain. Most notably, uptake of such AgAb by APC is










R, such as neutrophils and platelets. Previous re-
search by Gosselin et al. (8) revealed that Ag presentation by
human monocytes could be enhanced 100- to 1,000–fold by




RI on monocytes using chemical


















constructs would also be an effective way to increase the im-
munogenicity of peptides. To test this hypothesis, a Th cell
epitope of TT, TT830 (TT830-844) (9), was genetically grafted





to generate a fusion protein, Fab22-TT830. Presentation of
peptide TT830 expressed in the fusion protein Fab22-TT830




 1,000-fold more efficient than presentation
of the peptide alone. These results suggest that specific mAb-
based targeting to APCs may have important implications in
the development of peptide vaccines.
Peptides containing one or two amino acid changes from
native T cell epitopes, termed altered peptide ligands (APL)
by Allen and co-workers, have been shown to be agonists, par-
tial agonists, or antagonists for T cell activation (10, 11). Rec-
ognition of APL by specific T cells through T cell receptor














) modulation of Th1/
Th2 differentiation (15–17). Furthermore, immunizing mice
with APLs of encephalitogenic peptides of myelin proteolipid
protein (PLP) led to the inhibition of PLP peptide-induced ex-
perimental autoimmune encephalomyelitis (EAE) in suscepti-
ble mice (15, 18, 19), indicating that APL-based treatment may
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provide an antigen-specific immunotherapy for T cell–medi-
ated autoimmune diseases such as rheumatoid arthritis and
multiple sclerosis (15, 18–20). However, since peptides are
poorly presented in vivo, nearly 10 times more APL than
pathogenic PLP peptide had to be used in association with ad-
juvants in order to effectively inhibit EAE. To determine




RI might improve the pre-
senting efficiency of APL, the influence of targeted APL on
the activation of peptide-specific T cells was examined. An an-
tagonist peptide for TT830, TT833S (833K changed to 833S)





RI-targeted fusion protein Fab22-TT833S was generated.




 100 times more effective
than TT833S alone for inhibition of TT830-stimulated T cell
proliferation. These studies have revealed, for the first time, a
novel approach to enhance the efficiency of TCR antagonists
and thus may have potentially important implications in devel-







AIM V (Gibco Laboratories, Grand Island, NY) was used
as culture medium. TT was purchased from Accurate Chemical Co.























Her2/neu tumor Ag mAb 520C9), were provided by Medarex, Inc.
(Annandale, NJ). The universal Th epitope of TT, TT830-844 (QYI-
KANSKFIGITEL, termed as TT830 hereafter) (9), and the mutant
form of this epitope, TT833S (QYISANSKFIGITEL, lysine at posi-





by Peptidogenic Co. (Livermore, CA). Another universal Th epitope





 80% pure) (9), was provided by Dr. William
Hickey (Dartmouth Medical School, Hanover, NH) and was used as
a control peptide in this study. Commercially available human IgG









obtained from American Type Culture Collection (Rockville, MD).




, peptide TT830-specific T cells was
modified from a previously described protocol for TT-specific T cell
lines (8). Briefly, mononuclear cells were isolated from peripheral








 mononuclear cells were stimu-













 incubator, nonattached (mostly non-
specific cells) were removed by washing the flask once with 10 ml of
Hepes-buffered RPMI 1640; specific T cell colonies together with ad-
herent monocytes remained in the flask. 50 ml of AIM-V plus 20 U/
ml of human IL-2 (Immunex, Seattle, WA) and 1 ml (2%, final con-
centration) pooled human serum were added back to the flask. After
10–14 d of total incubation time, T cells were harvested and dead cells
were pelleted through Ficoll-Hypaque, yielding a highly enriched




, Ag-specific T cells. The T cells
were confirmed to be specific for TT830 peptide as shown in Fig. 3.
Large quantities of monocytes were purified from leukophoresis
packs using the cold aggregation method (22) which resulted in 80–
90% purity. Both monocytes and T cells were frozen in aliquots for

















/well), and various concentra-
tions of peptide TT830 or fusion protein Fab22-TT830 were incu-




l/well in flat-bottomed 96-













then added to each well. After incubating overnight, plates were har-
vested and counted in a liquid scintillation counter. T cell prolifera-





SD. Background CPM (T cells and monocytes without
Ag) was subtracted from all the data points. Experiments with APL
were done according to similar protocols reported by Sette and co-
workers (21). Briefly, for inhibition assays, irradiated monocytes
were treated with various concentrations of TT833S or Fab22-
TT833S overnight. 20 nM TT830 and T cells were then added. After a
further 2 d of incubation, T cell proliferation was measured as de-
scribed above. In prepulsing experiments, irradiated monocytes were
pulsed with 20 nM TT830 for 4 h. These cells were then washed









M Fab22-TT833S. After overnight incubation, T cells
were then added. After a further 2 d of incubation, T cell prolifera-
tion was measured as described above. In T cell anergy induction as-
says, T cells were stimulated with irradiated monocytes and TT833S
or Fab22-TT833S for 1 d, recovered after centrifugation over Ficoll-
Hypaque, and restimulated with monocytes and various concentra-





H]thymidine and the average CPM of three repli-
cates was plotted. In some cases, the percentage of inhibition was cal-


































 100. All experiments were repeated at least three
times.
 
Staining and flow cytometry.
 
Staining procedures were adapted
from those previously described (23). Briefly, to individual wells of a








l of myeloid cell line U937 cells was added.








 1 mg/ml BSA containing one of
the proteins Fab22-TT830, Fab22-TT833S, or the BsAb MDXH210





centrifuged, the supernatants were discarded, and the cells were




C. Cells were then incubated












 goat anti–human IgG
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) fol-
lowed by three washes with PBS/BSA and resuspended in PBS/BSA
containing 1% paraformaldehyde (Eastman Kodak, Rochester, NY).




 (Becton Dickinson, Moun-




Supernatants were collected from the 96-
well plates of Ag presentation assays after 2 d of stimulation and fro-




 and IL-4 from these samples were





cific ELISA were purchased from Pharmingen (San Diego, CA).
ELISA assays were performed according to the protocol provided by
the manufacturer.
 
Generation of H22-TT peptide fusion proteins.
 
To generate fu-
sion proteins Fab22-TT830 and Fab22-TT833S, synthetic oligonucle-
otides encoding each peptide were separately engineered into the





(H22) according to a method we have developed (Graziano, J., R.F.
Goldstein, K. Sundarapandiyan, C. Somasundaram, and Y. Deo,
manuscript submitted for publication). The procedures are briefly de-
scribed as follows.
 
Expression and cloning vectors.
 
mAb 22 has been humanized by
grafting its CDR regions into a human IgG1 framework (24). The ex-
pression vector for the genomic clone of the heavy chain (pSVgpt) of
H22 was modified to allow incorporation of the coding sequence for
other molecules, in this case the TT peptides. The BamHI fragment
of this vector containing CH1, hinge, and newly engineered XhoI and
NotI cloning sites was inserted into the BamHI site of pUC19 to gen-




 N). This vector was used to
clone oligonucleotide sequences encoding TT peptides, as described
below.
The oligonucleotide sequences encoding the TT peptides were




 terminus and a NotI site on





cleotides were synthesized and purified by Genosys Biotechnologies,
Inc. (The Woodlands, TX). The synthetic oligonucleotides were then
 












N). Clones which had incorporated the coding sequences for TT pep-
tides were screened by restriction mapping. The BamHI fragment
containing CH1, hinge, and TT830 or TT833S was then cut out of
pUC19 and inserted into the expression vector which already con-
tained VH. The final expression construct of H22 heavy chain fused








The murine myeloma NSØ (ECACC 85110503) is a
non-Ig synthesizing line and was used for expression of the H22-TT
fusion proteins. First, NSØ cells were transfected with the pSVhyg
vector containing the H22 light chain coding sequence. The H22 light
chain expressing NSØ cells was then transfected with the expression
vector construct containing the H22 H-chain Fd sequence fused in




). An electroporation ap-
paratus (Gene Pulser; Bio-Rad Laboratories, Richmond, VA) was




F. 1 or 2 d af-




g/ml; Sigma Chemical Co.,




g/ml; Sigma Chemical Co.) were
added to the media to select transfectants which had successfully
taken up the expression vectors. Individual colonies were isolated





U937 cells as demonstrated by flow cytometry. The positive colonies




Clone pW5 expressing the Fab22-TT830 fusion pro-
tein and clone pM4 expressing the Fab22-TT833S fusion protein were
expanded in roller bottle cultures. The supernatants were clarified
and concentrated. Small scale purification was performed by affinity
chromatography on an anti-H22 affinity column. SDS-PAGE analysis









 90% pure and had a mo-
lecular mass of 50 kD as expected. Protein concentration was deter-













H22 fusion proteins bind to U937 cells.
 
The ability of H22 fu-





RI was examined first. A previously described bispecific









 of humanized mAb 22) (25), was used as a posi-
tive control. Binding of fusion proteins and MDXH210 to





by staining with FITC-labeled goat Ab specific for human IgG
and flow cytometry. As indicated in Fig. 2, the fusion proteins
Fab22-TT830 and Fab22-TT833S bound to U937 cells in a
manner similar to MDXH210. The binding of fusion proteins




















H22 fusion protein enhances presentation of peptide by
100- to 1,000-fold.
 
The fusion protein Fab22-TT830 was used
in Ag presentation assays to determine whether the Th
epitope, TT830, when expressed in the constant region of H22,
could be effectively presented by monocytes to autologous T
cells. Three T cell lines specific for TT830 were separately gen-




 1,000-fold less Fab22-TT830 was required than TT830 pep-
tide to achieve the same level of T cell proliferation. This ex-
periment was repeated for each cell line, and although each ex-
hibited a somewhat different dose–response to TT830, 500- to
1,000-fold enhancement of Ag presentation mediated by the
fusion protein Fab22-TT830 was consistently observed. In ad-





 10,000-fold more efficient than the presentation of the
intact TT, suggesting that the enhanced presentation of Fab22-
TT830 did not merely result from higher molecular weight or
increased stability of Fab22-TT830 as opposed to TT830 pep-
tide. Another antigenic TT epitope, TT947, failed to stimulate
the T cells, confirming that the T cells were specific for TT830
peptide. Thus, these results provide clear evidence that Th
epitopes expressed in the constant region of H22 can be specif-






RI on monocytes abrogates the enhance-
ment of Ag presentation by the fusion protein.
 
To directly de-
Figure 1. Generation of H22-TT peptide 
fusion proteins. (A) The sequence of the 
synthetic oligonucleotides encoding TT 
peptides. (B) Map of the final genetic con-







termine whether the enhancement of peptide presentation









RI on Ag-presenting monocytes













 for 1 h before the addition of
Fab22-TT830 or TT830 peptides at various concentrations.
Enhancement of peptide presentation by the fusion protein
was abrogated by mAb 22 F(ab
 
9)2, whereas presentation of
TT830 was unaffected (Fig. 4). The fact that the binding of free
mAb 22 F(ab9)2 to FcgRI did not lead to an enhancement of
the presentation of free peptides implies that binding of mAb
22 to FcgRI alone did not alter the functional state of mono-
cytes in a way that enhanced Ag presentation. Therefore, link-
age of the peptide to anti-FcgRI Ab 22 appears to be neces-
sary for the observed enhancing effects on Ag presentation,
suggesting that the enhanced presentation is probably a result
of efficient Ag capture through FcgRI. In addition, the en-
hanced presentation of the TT830 peptide using the fusion
protein Fab22-TT830 was not inhibited by IgG (data not
shown), in agreement with previous studies showing that mAb
22 binds to an epitope of FcgRI outside the ligand binding do-
main and can thus trigger FcgR-mediated functions without
inhibition by physiological levels of IgG (8, 26).
IFN-g and IL-4 production is increased after Fab22 fusion
protein-enhanced Ag presentation. Upon activation, T cells
not only undergo clonal expansion through proliferation, but
also produce cytokines such as IFN-g and IL-4 to exert their
effector function on B cell differentiation and monocyte acti-
vation (27). Therefore, the production of IFN-g and IL-4 after
H22 fusion protein-enhanced Ag presentation was examined.
As shown in Fig. 5, A and B, both IFN-g and IL-4 production
levels were enhanced by Fab22-TT830, especially at subopti-
mal Ag concentrations. However, in these experiments, the
Figure 2. H22-TT pep-
tide fusion proteins 
maintain the binding 
ability to FcgRI on 
U937 cells. U937 cells 
were first incubated at 
48C for 1 h with saturat-
ing concentration
(5 mg/ml) of either fu-
sion proteins Fab22-
TT830, Fab22-TT833S, 
or a positive control, 
bispecific Ab, 
MDXH210, followed 
by FITC-labeled goat 
anti–human IgG Abs as 
described in Methods. 
During the first incuba-
tion, 100 mg/ml murine 
mAb 22 F(ab9)2 was 
added to some wells to 
block the binding of fu-
sion proteins or 
MDXH210. Samples 
were then analyzed by 
FACScan®. Fluores-
cence histograms for 
the three samples at
5 mg/ml of fusion pro-
tein are plotted. The 
dashed lines represent 
negative controls in 
which U937 cells were 
incubated in medium 
only followed by sec-
ondary Ab. The solid 
lines denote the stain-
ing by fusion proteins 
or MDXH210 and the 
dotted lines represent 
fusion protein binding 
blocked by murine 
mAb 22 F(ab9)2.
Figure 3. The fusion protein Fab22-TT830 enhances the presentation 
of the Th epitope by z 1,000-fold. The Ag presentation assay was 
performed as described in Methods. Four different forms of Ag were 
used in the experiments, antigenic peptide TT830, fusion protein 
Fab22-TT830, whole TT, and irrelevant Th epitope on TT, TT947. 
The concentration of Ag is indicated on the x axis.
Figure 4. The enhanced presentation of fusion protein Fab22-TT830 
is FcgRI dependent. A saturating concentration of mAb 22 F(ab9)2 
(10 mg/ml) was added to monocytes at the appropriate wells 1 h be-
fore the addition of Ag and T cells. The Ag presentation assay was 
then completed as in Fig. 3. The concentration of Ag is indicated in 
the x axis.
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enhancement for cytokine production (z 20-fold) was less
than that for T cell proliferation (z 600-fold).
Fab22-TT833S is at least 100 times more effective than
TT833S in inhibiting T cell activation. We next performed ex-
periments to determine whether the activity of an APL could
be enhanced by FcgRI-targeting. To do this, we synthesized
TT833S peptide, an antagonist peptide for T cell epitope
TT830. As shown in Fig. 6, even at doses as high as 100 mM for
TT833S and 1 mM for Fab22-TT833S, no significant prolifera-
tion of TT830-specific T cells was observed. Both peptide
TT833S and Fab22-TT833S also failed to stimulate the produc-
tion of IFN-g or IL-4 (data not shown). This indicates that
changing lysine to serine at position 833 of the TT830 peptide
eliminated T cell reactivity of this T cell epitope. Additionally,
when peptides TT830 and TT833S were simultaneously pre-
sented to TT830-specific T cells, T cell proliferation in re-
sponse to TT830 was inhibited by TT833S in a dose-dependent
fashion, showing that TT833S can function as an antagonist for
TT830-specific T cells (Fig. 7). Furthermore, Fab22-TT833S
was z 100 times more effective than TT833S in inhibiting
TT830-stimulated T cell proliferation (Fig. 7). This suggests
that the APL, TT833S, when expressed in the constant region
of mAb H22, can be correctly and effectively presented by
APC. The increased antagonistic efficacy of fusion protein
Fab22-TT833S on T cell proliferation probably reflects more
efficient Ag capture mediated by FcgRI as compared with free
peptides.
Inhibition appears to be a result of competition for TCR
rather than for MHC class II binding. The antagonist effects
of APL TT833S and fusion protein Fab22-TT833S might be
through competition at the level of MHC-binding or TCR-
binding, or both. To gain insight into the mechanisms involved,
prepulsing experiments, first described by Sette and co-work-
ers (21), were performed. This experimental setting allows ag-
onist (TT830) to bind to MHC class II in the absence of com-
petition from the inhibitor (TT833S), and thus only TCR
antagonists but not pure MHC blockers would be effective in
Figure 5. Presentation of TT830 and Fab22-TT830 stimulates IFN-g 
and IL-4 production. Supernatants from Ag presentation assays (de-
scribed in Fig. 3) were collected after 2 d of stimulation. The levels of 
IFN-g and IL-4 were assayed by ELISA and are plotted in A and B, 
respectively.
Figure 6. Presentation of APL with use of TT833S or Fab22-TT833S 
fusion protein fails to stimulate T cell proliferation. The concentra-
tions of Ag are indicated on the x axis while T cell proliferation 
(CPM) is plotted in the y axis. Experiments were done as in Fig. 3.
Figure 7. Fab22-TT833S is z 100 times more effective than TT833S 
in inhibiting T cell activation. Monocytes were incubated with various 
concentrations of TT833S or Fab22-TT833S overnight. 20 nM TT830, 
which stimulates 50% of the maximal T cell response, and T cells 
were then added. After a further 2 d of incubation, T cell prolifera-
tion was measured. The percentage of inhibition was calculated as de-
scribed in Methods.
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inhibiting agonist-stimulated T cell proliferation (21). Specifi-
cally, Ag-presenting monocytes were pulsed for 4 h with a con-
centration (20 nM) of TT830, which stimulated 50% of the
maximal response of this particular T cell line. This permitted
TT830 to bind with MHC class II in the absence of competi-
tion from TT833S. The APL, TT833S or Fab22-TT833S, was
then incubated with the prepulsed monocytes for an additional
16 h. Responding T cells were added and their proliferation
was measured as usual. Even under such conditions where
MHC blockade plays a minimal role, T cell proliferation was
still inhibited. T cell antagonism by the fusion protein Fab22-
TT833S was at least 100-fold more efficient than by the nontar-
geted antagonist, TT833S (Fig. 8). Thus, the inhibition appears
to be a result of competition for TCR rather than for MHC
class II binding.
Discussion
The observation that immunogenicity is increased by up to
1,000-fold by targeting antigenic peptides to FcgRI using an
anti-FcgRI mAb 22–based fusion protein reveals a potentially
useful vehicle for peptide-based vaccines for infectious dis-
eases and cancer. This peptide-targeting method has several
distinct advantages over the AgAbs previously described by
other investigators (6, 7). Since the binding site for H22 fusion
proteins is outside the ligand-binding domain of FcgRI, there
is no competition for their binding to APC from abundant se-
rum IgG (8, 26, and data not shown). This contrasts with the
binding of AgAb to FcgRI, which would be adversely affected
by competing serum IgG, preventing APCs from efficiently
concentrating the Ags. Furthermore, H22 fusion proteins bind
only to FcgRI which in healthy subjects is restricted to mono-
cytes, macrophages, and dendritic cells (28), all of which are
“professional” APCs. AgAb, on the other hand, could be se-
questered by a variety of FcgRII or FcgRIII-bearing non-
APCs such as neutrophils and platelets. Engineering peptides
into the constant domains of human mAb that are specific for
particular APC surface molecules may thus represent a gen-
eral approach to increase the antigenic potency for peptide-
based vaccines. The resultant constructs would bind very selec-
tively to professional APCs in vivo where Ag dilution and the
short half-life of peptides would be even more significant than
in the cell culture system studied thus far. In addition, target-
ing Ag to FcgR, or to different molecules on APCs, might
have the potential to qualitatively alter the type of response
elicited.
Studies reported in this paper have demonstrated that Th
epitopes expressed in the constant region of anti-FcgRI mAb
H22 can be effectively processed and presented by human
monocytes, leading to enhanced T cell activation and cytokine
production (Figs. 3–5). The effective presentation of the fusion
protein Fab22-TT830 appears to result from more efficient Ag
capture through specific binding to FcgRI, as the murine mAb
22 abrogated the enhancement in Fab22-TT830 presentation
but had no effect on T cell stimulation by the nontargeted pep-
tide TT830 (Fig. 4). Furthermore, the antagonistic peptide,
TT833S, similarly expressed in the constant region of H22,
could also be effectively presented by monocytes. As a result,
the fusion protein Fab22-TT833S was z 100 times more effec-
tive than free TT833S in antagonizing T cell activation stimu-
lated by the wild-type peptide TT830 (Figs. 7 and 8).
Our studies also revealed the potentially interesting phe-
nomenon that the FcgRI-targeted fusion protein Fab22-TT830
enhanced T cell proliferation by up to 1,000-fold as compared
with the peptide TT830 (Figs. 3 and 4), whereas enhancement
of cytokine (IFN-g and IL-4) production by Fab22-TT830 was
only 20-fold (Fig. 5). This difference in the stimulation of T cell
proliferation and cytokine production is in agreement with
previous studies of TCR partial agonists showing that cellular
proliferation and cytokine production are separable events of
T cell activation and probably require different degrees of in-
teraction between accessory molecules (29, 30). Another possi-
ble explanation is that the FcgRI-targeted fusion protein
Fab22-TT830 alters the production by monocytes of IL-10 and
IL-12, both of which are known to significantly influence the
production of IFN-g and IL-4 by T cells. We are currently de-
veloping similar fusion proteins consisting of Fab22 and spe-
cific epitopes of the model antigen ovalbumin. These fusion
proteins will enable us to evaluate differential stimulation of T
cell proliferation and cytokine production using a well-defined
mouse model system (31).
APLs, peptides with one or more point mutations from a
Th epitope, have been reported to act as agonists, partial ago-
nists, or antagonists (10, 11). Agonist peptides retained the full
activity of wild-type peptides to stimulate T cell activation. As
mentioned above, partial agonists stimulated some T cell func-
tions such as IL-4 production by T cells, but not others such as
T cell proliferation (29). In some cases, partial agonists were
capable of inducing T cell anergy (13, 14). Certain APLs do
not trigger any detectable signaling events upon interaction
with TCR, but can function as TCR antagonists to inhibit T
cell proliferation in response to wild-type peptide antigen and
are thus called TCR antagonists (21, 32). In this study, the al-
tered peptide TT833S did not stimulate proliferation or the
production of IL-4 and IFN-g by T cells specific for the native
peptide TT830 (Fig. 6 and data not shown). TT833S also failed
to induce T cell anergy. However, TT833S did inhibit the pro-
liferation of TT830-specific T cells responding to TT830, indi-
cating that TT833S belongs in the category of antagonists first
described by Sette and co-workers (21).
Figure 8. APL-mediated inhibition appears to be a result of competi-
tion for TCR rather than for MHC class II binding. Monocytes were 
pulsed with 20 nM TT830, which stimulates 50% of the maximal T 
cell response, 4 h before the addition of various concentrations of 
TT833S or 0.1 mM Fab22-TT833S. After overnight incubation, T cells 
were then added. After a further 2 d of incubation, T cell prolifera-
tion was measured.
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The results reported here have potentially important impli-
cations for the use of TCR antagonists as Ag-specific therapy
for autoimmune diseases. The therapeutic potential of APL in
autoimmune diseases has been demonstrated by in vivo treat-
ment using altered encephalitogenic peptides of PLP, which
led to the inhibition of PLP-induced EAE in susceptible mice
(18, 19). Similar APL-based treatment could provide an anti-
gen-specific immunotherapy for T cell–mediated autoimmune
diseases such as rheumatoid arthritis and multiple sclerosis.
However, the efficacy for this kind of APL-based treatment of
autoimmune diseases is limited by the fact that peptides are
poorly presented in vivo, and thus coadministration of adju-
vant has been necessary for the in vivo effects in mice. We
have demonstrated (Fig. 8) that FcgRI-targeted APL can effi-
ciently antagonize activation of native peptide-reactive T cells
even when the APC has been prepulsed with native peptide
sufficient for T cell activation. In addition, we have previously
shown that the parent molecule of the fusion proteins de-
scribed in this report, humanized mAb 22, specifically and effi-
ciently binds to human FcgRI in vivo and is an unusually po-
tent immunogen (31). Thus, targeting of APL to FcgRI using
mAb 22–based fusion proteins may efficiently deliver APLs to
APCs in an adjuvant-free manner in vivo and may effectively
inhibit the activation of autoreactive T cells. Overall, the ap-
proaches described in this report may lead to more potent vac-
cines and to promising Ag-specific treatments for autoimmune
diseases.
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